Baker Bros. Advisors Lp buys $75,653,091 stake in BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals (BCRX) : Baker Bros. Advisors Lp scooped up 792,755 additional shares in BioCryst Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 15,010,534 shares of BioCryst Pharmaceuticals which is valued at $75,653,091.BioCryst Pharmaceuticals makes up approximately 0.84% of Baker Bros. Advisors Lp’s portfolio.

Other Hedge Funds, Including , D. E. Shaw boosted its stake in BCRX in the latest quarter, The investment management firm added 1,487,851 additional shares and now holds a total of 4,055,066 shares of BioCryst Pharmaceuticals which is valued at $20,437,533. BioCryst Pharmaceuticals makes up approx 0.04% of D. E. Shaw’s portfolio. Dynamic Technology Lab Private Ltd sold out all of its stake in BCRX during the most recent quarter. The investment firm sold 19,107 shares of BCRX which is valued $96,299.California Public Employees Retirement System reduced its stake in BCRX by selling 4,200 shares or 3.08% in the most recent quarter. The Hedge Fund company now holds 132,000 shares of BCRX which is valued at $531,960.

BioCryst Pharmaceuticals opened for trading at $4.12 and hit $4.25 on the upside on Thursday, eventually ending the session at $4.16, with a gain of 1.22% or 0.05 points. The heightened volatility saw the trading volume jump to 3,93,134 shares. Company has a market cap of $307 M.

On the company’s financial health, BioCryst Pharmaceuticals reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.26. The company had revenue of $4.80 million for the quarter, compared to analysts expectations of $4.33 million. The company’s revenue was down -81.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.06 EPS.

Many Wall Street Analysts have commented on BioCryst Pharmaceuticals. BioCryst Pharmaceuticals was Upgraded by Piper Jaffray to ” Overweight” on Aug 12, 2016. BioCryst Pharmaceuticals was Downgraded by JMP Securities to ” Mkt Perform” on Aug 4, 2016.

BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company’s Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

BioCryst Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioCryst Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.